Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611026 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,417
- Enrollment target
NCT00611026 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 2,417 participants.
The verdict
NCT00611026, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,417 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
Interventions
- DRUG Placebo
- DRUG Fesoterodine
- DRUG Tolterodine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,417 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00611026
The ClinicalTrials.gov registry entry for NCT00611026 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,417 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00611026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00611026 about?
NCT00611026 is a clinical study titled "Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.". To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
What is the current status of trial NCT00611026?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,417 participants. The study started on 2008-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00611026?
The interventions under investigation include: Placebo (DRUG), Fesoterodine (DRUG), Tolterodine ER (DRUG).
Who is sponsoring clinical trial NCT00611026?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.